


Supplemental Figure S1. Mevalonate decreases directional ECFC migration and reduces pravastatin (2000 μ M) induced increase in directional migration. Representative images of DAPI-stained migrated ECFCs after treatment with 2000 μ M pravastatin with or without 200 μ M mevalonate. Con, control; Prava, pravastatin; Mev, mevalonate. Scale bar 150 μ m.



Supplemental Figure S2. Mevalonate (200 μ M) modulates pravastatin's effect on ECFCs' tube formation ability. Representative images of ECFCs' tube formation after 6 h in the presence of medium only (a), mevalonate (b), 20 μ M pravastatin (c), 20 μ M pravastatin + 200 μ M mevalonate (d), 2000 μ M pravastatin (e) or 2000 μ M pravastatin + 200 μ M mevalonate (f). Scale bar 500 μ m.